Vitamin C and D supplementation in acute myeloid leukemia.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
accepted:
22
07
2023
received:
26
04
2023
medline:
4
12
2023
pubmed:
6
9
2023
entrez:
6
9
2023
Statut:
ppublish
Résumé
Recent studies have highlighted the role of vitamin C and D in acute myeloid leukemia (AML). In 2018, we changed our practices to add both vitamins to the supportive care for all consecutive patients with AML undergoing intensive chemotherapy. In this study, we compared the outcomes of patients treated before and after this change in practice. From 2015 to 2020, 431 patients were included, 262 of whom received no supplementation and 169 of whom received vitamin supplementation. Vitamin C and vitamin D was administered from day 10 of chemotherapy until hematologic recovery from induction and consolidation. Most patients presented at diagnosis with low levels of vitamin C and D. Upon recovery from induction, vitamin D levels among the vitamin C/D group significantly increased compared with those at diagnosis, and pretransplant levels were significantly higher in the vitamin C/D group compared with the control group (median of 33 vs 19 ng/mL; P < .0001). During induction, the rates of bacterial or fungal infection, hemorrhage, or macrophage activation syndrome were lower in the vitamin C/D group, whereas there was no difference in response rate, relapse incidence, and overall survival (OS). However, the multivariate analysis for OS showed a significant interaction between vitamin C/D and NPM1 mutation, meaning that vitamin C/D supplementation was significantly and independently associated with better OS in patients with NPM1 mutations (hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.30-0.90; P = .019) compared with patients with wild-type NPM1 (HR, 1.01; 95% CI, 0.68-1.51; P = .95). In conclusion, vitamin C/D supplementation is safe and could influence the outcomes of patients with AML undergoing intensive chemotherapy.
Identifiants
pubmed: 37671973
pii: 497750
doi: 10.1182/bloodadvances.2023010559
pmc: PMC10685150
doi:
Substances chimiques
Ascorbic Acid
PQ6CK8PD0R
Nucleophosmin
117896-08-9
Vitamins
0
Vitamin D
1406-16-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6886-6897Informations de copyright
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Leuk Res. 2018 Mar;66:1-7
pubmed: 29331774
Cancer Discov. 2013 Jul;3(7):730-41
pubmed: 23796461
Cell Rep. 2020 Jan 21;30(3):739-754.e4
pubmed: 31968250
Nat Rev Mol Cell Biol. 2013 Jun;14(6):341-56
pubmed: 23698584
Nature. 2017 Sep 28;549(7673):476-481
pubmed: 28825709
Integr Cancer Ther. 2014 Jul;13(4):280-300
pubmed: 24867961
Cold Spring Harb Perspect Med. 2017 Aug 1;7(8):
pubmed: 28242787
Biol Blood Marrow Transplant. 2019 Oct;25(10):2079-2085
pubmed: 31229642
J Clin Oncol. 2018 Sep 10;36(26):2684-2692
pubmed: 30024784
Nat Rev Clin Oncol. 2021 Oct;18(10):645-661
pubmed: 34131315
J Clin Oncol. 2017 Sep 20;35(27):3143-3152
pubmed: 28771378
N Engl J Med. 2007 Jul 19;357(3):266-81
pubmed: 17634462
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Leukemia. 2018 Jan;32(1):11-20
pubmed: 28663574
Cancer Lett. 2012 Jun 1;319(1):8-22
pubmed: 22193723
J Clin Invest. 1986 Aug;78(2):424-30
pubmed: 3461004
Leuk Res. 2023 Feb;125:107001
pubmed: 36566538
N Engl J Med. 2017 Aug 3;377(5):454-464
pubmed: 28644114
Cancers (Basel). 2021 Oct 19;13(20):
pubmed: 34680392
Exp Hematol. 1986 Jan;14(1):60-5
pubmed: 3510890
Nutrients. 2020 Jul 15;12(7):
pubmed: 32679784
Nutrients. 2017 Nov 03;9(11):
pubmed: 29099763
Cancer Cell. 2010 Dec 14;18(6):553-67
pubmed: 21130701
J Cell Physiol. 2008 Oct;217(1):207-14
pubmed: 18481258
Blood Cancer J. 2019 Oct 2;9(10):82
pubmed: 31578317
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Exp Hematol. 2017 Jun;50:1-12
pubmed: 28174131
Cell. 2017 Sep 7;170(6):1079-1095.e20
pubmed: 28823558
Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10238-44
pubmed: 27573823
Front Cell Dev Biol. 2022 Jul 22;10:930205
pubmed: 35938170
Bone Marrow Transplant. 2020 Nov;55(11):2060-2070
pubmed: 32335583
Blood Adv. 2022 Mar 8;6(5):1499-1511
pubmed: 34496015
Results Immunol. 2016 Jan 12;6:8-10
pubmed: 27014565
Front Oncol. 2022 Jun 27;12:890344
pubmed: 35832559
Nat Rev Cancer. 2020 Jul;20(7):365-382
pubmed: 32415283
Leuk Res. 2014 May;38(5):638-47
pubmed: 24703772
Cancer. 2014 Feb 15;120(4):521-9
pubmed: 24166051